Laddar...
Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxici...
Sparad:
| I publikationen: | BMC Med Res Methodol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4234400/ https://ncbi.nlm.nih.gov/pubmed/24731155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2288-14-51 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|